Immunic (IMUX) Projected to Post Quarterly Earnings on Thursday

Key Points

• Immunic will report Q4 2025 results before the market opens on Feb 26, 2026, with analysts forecasting earnings of ($0.1022) per share and an earnings call scheduled for 9:30 AM ET.
• Shares opened at $0.88 on Thursday, down 4.4%, valuing the company at about $105.51 million with a 12‑month range of $0.51–$1.39 and short‑term moving averages near the current price.
• Institutional ownership is ~51.82% after recent large purchases by Nantahala, Millennium, Laurion and others, and analysts skew positive — consensus rating "Buy" with an average price target of about $6.60 (range roughly $3–$8).

Immunic (NASDAQ:IMUX - Get Free Report) will likely be posting its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.1022) per share for the quarter. Individuals may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

Immunic Stock Down 4.4%

Shares of Immunic stock opened at $0.88 on Thursday. The firm has a market cap of $105.51 million, a price-to-earnings ratio of -1.06 and a beta of 1.58. The business has a 50-day moving average price of $0.65 and a 200-day moving average price of $0.76. Immunic has a twelve month low of $0.51 and a twelve month high of $1.39.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of IMUX. Nantahala Capital Management LLC acquired a new stake in shares of Immunic in the fourth quarter valued at about $2,337,000. Millennium Management LLC lifted its stake in Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company's stock worth $1,825,000 after acquiring an additional 2,888,829 shares in the last quarter. Laurion Capital Management LP lifted its holdings in Immunic by 106.3% during the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company's stock worth $2,072,000 after buying an additional 2,000,000 shares in the last quarter. Marshall Wace LLP boosted its holdings in Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company's stock valued at $541,000 after purchasing an additional 486,468 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in Immunic in the third quarter worth approximately $239,000. 51.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

IMUX has been the subject of a number of recent research reports. D. Boral Capital cut their target price on shares of Immunic from $8.00 to $4.00 and set a "buy" rating for the company in a report on Friday, February 13th. Roth Mkm assumed coverage on shares of Immunic in a research note on Friday, November 7th. They issued a "buy" rating and a $3.00 target price on the stock. Brookline Capital Acquisition raised shares of Immunic to a "strong-buy" rating in a research note on Tuesday, February 3rd. HC Wainwright reaffirmed a "buy" rating and set a $8.00 target price on shares of Immunic in a research report on Monday, February 9th. Finally, Chardan Capital raised shares of Immunic to a "strong-buy" rating in a report on Wednesday, November 19th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immunic presently has an average rating of "Buy" and a consensus price target of $6.60.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company's research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic's lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn's disease and relapsing multiple sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.